Profile data is unavailable for this security.
About the company
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. It has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The Company conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
- Revenue in AUD (TTM)291.02k
- Net income in AUD-13.04m
- Incorporated1999
- Employees--
- LocationActinogen Medical LtdSelect HouseSE 901 L 9, 109 Pitt StreetSYDNEY 2000AustraliaAUS
- Phone+61 28964-7401
- Fax+61 28964-7588
- Websitehttps://actinogen.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cynata Therapeutics Ltd | 417.71k | -9.74m | 38.85m | 0.00 | -- | 5.35 | -- | 93.00 | -0.0543 | -0.0543 | 0.0023 | 0.0402 | 0.0305 | -- | 1.85 | -- | -71.18 | -39.49 | -81.37 | -42.96 | -- | -- | -2,332.89 | -515.32 | -- | -- | 0.00 | -- | 18.38 | 16.51 | 31.75 | -- | -- | -- |
| IDT Australia Limited | 14.12m | -5.41m | 42.98m | 156.00 | -- | 1.50 | -- | 3.04 | -0.0154 | -0.0154 | 0.0404 | 0.0667 | 0.4734 | 1.84 | 2.62 | -- | -18.15 | -9.77 | -22.59 | -11.61 | 80.11 | 84.61 | -38.33 | -23.12 | 1.12 | -50.05 | 0.1601 | -- | 100.81 | 3.09 | 36.30 | -- | -10.39 | -- |
| Tryptamine Therapeutics Ltd | -100.00bn | -100.00bn | 55.19m | -- | -- | 9.12 | -- | -- | -- | -- | -- | 0.0049 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0342 | -- | -- | -- | -- | -- | -- | -- |
| Anteotech Ltd | 514.89k | -8.88m | 58.27m | 40.00 | -- | 9.38 | -- | 113.18 | -0.0039 | -0.0039 | 0.0002 | 0.0021 | 0.0699 | -- | 2.55 | -- | -120.47 | -75.24 | -159.35 | -84.74 | -- | -- | -1,724.74 | -1,444.66 | -- | -- | 0.3055 | -- | 26.85 | 27.93 | 29.82 | -- | 68.39 | -- |
| Neurotech International Ltd | 3.34m | -5.07m | 69.32m | -- | -- | 5.73 | -- | 20.78 | -0.0054 | -0.0054 | 0.0037 | 0.0117 | 0.3807 | 0.00 | 11.59 | -- | -57.86 | -134.56 | -63.92 | -163.66 | 100.00 | -- | -151.98 | -462.38 | 38.81 | -- | 0.00 | -- | 165.98 | 67.39 | 34.94 | -- | -- | -- |
| Actinogen Medical Ltd | 291.02k | -13.04m | 73.98m | -- | -- | 3.31 | -- | 254.22 | -0.0061 | -0.0061 | 0.0001 | 0.0072 | 0.0159 | -- | 0.0433 | -- | -71.44 | -48.56 | -78.20 | -51.97 | -- | -- | -4,482.26 | -5,188.44 | -- | -163.10 | 0.0159 | -- | -20.63 | 7.31 | -21.32 | -- | -- | -- |
| Percheron Therapeutics Ltd | 615.48k | -11.92m | 76.72m | 8.00 | -- | 7.13 | -- | 124.65 | -0.0135 | -0.0135 | 0.0007 | 0.0104 | 0.045 | -- | 0.2912 | -- | -87.09 | -75.92 | -122.82 | -89.91 | -- | -- | -1,936.57 | -4,028.81 | -- | -1,956.65 | 0.0042 | -- | 59.90 | 56.21 | -4.74 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 1.41m | -6.38m | 87.77m | -- | -- | 9.32 | -- | 62.27 | -0.0507 | -0.0507 | 0.0112 | 0.0719 | 0.1346 | -- | 6.45 | -- | -61.88 | -60.46 | -67.65 | -69.49 | -- | -- | -459.82 | -290.18 | -- | -208.63 | 0.0331 | -- | -4.24 | -1.45 | -3.23 | -- | 60.39 | -- |
| Argenica Therapeutics Ltd | 192.09k | -5.48m | 92.87m | -- | -- | 6.43 | -- | 483.46 | -0.0518 | -0.0518 | 0.0019 | 0.1128 | 0.0148 | -- | 0.7326 | -- | -42.28 | -- | -50.70 | -- | -- | -- | -2,852.56 | -- | -- | -21,829.87 | 0.00 | -- | 214.90 | -- | -13.80 | -- | -- | -- |
| Paradigm Biopharmaceuticals Ltd | 6.52m | -58.65m | 94.49m | -- | -- | 3.97 | -- | 14.49 | -0.1875 | -0.1875 | 0.0186 | 0.068 | 0.138 | -- | 1.10 | -- | -124.19 | -52.89 | -150.28 | -58.06 | 99.86 | -- | -899.60 | -543.63 | -- | -961.47 | 0.006 | -- | -23.22 | 14.97 | -12.99 | -- | -- | -- |
| LTR Pharma Ltd | 49.00k | -6.95m | 103.87m | -- | -- | 58.08 | -- | 2,119.73 | -0.0499 | -0.0499 | 0.0004 | 0.0211 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14,192.84 | -- | -- | -414.02 | 0.00 | -- | -- | -- | -378.00 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 24 Sep 2024 | 247.33m | 8.40% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 11.37k | 0.00% |
